Celcuity just scored its first-ever FDA approval for its blockbuster breast cancer drug, Revtorpyk—yet the stock immediately cratered by over 20%. Why did a massive medical milestone trigger an absolute bloodbath? Because Wall Street has zero patience for near-term launch hurdles, getting spooked by weekly clinic infusion logistics and a ticking cash-burn clock. In this episode of Implied, we break down why the market is completely ignoring a staggering 76% reduction in cancer progression risk, and whether this brutal selloff is a warning sign of a slow rollout... or a rare, deep discount on a validated biotech player with massive buyout potential. Tune in to find out!